Coherus Oncology, Inc.
Coherus Oncology, Inc. (Nasdaq: CHRS) is a fully integrated commercial-stage innovative oncology company focused on developing and commercializing proprietary immuno-oncology medicines. The company changed its corporate name from Coherus BioSciences, Inc. to Coherus Oncology, Inc. in May 2025 to reflect its exclusive… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Coherus Oncology, Inc. does
In the company’s own words
Coherus Oncology, Inc. (Nasdaq: CHRS) is a fully integrated commercial-stage innovative oncology company focused on developing and commercializing proprietary immuno-oncology medicines. The company changed its corporate name from Coherus BioSciences, Inc. to Coherus Oncology, Inc. in May 2025 to reflect its exclusive focus on immuno-oncology following recent divestitures of its biosimilar businesses.
The company's primary product is LOQTORZI (toripalimab-tpzi), a next-generation programmed death receptor-1 (PD-1) inhibitor approved by the FDA in October 2023 for treating nasopharyngeal carcinoma. LOQTORZI is approved in combination with cisplatin and gemcitabine for first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma, and as monotherapy for recurrent unresectable or metastatic disease with progression after platinum-containing chemotherapy. The company launched LOQTORZI in the United States in January 2024 and represents the only FDA-approved immunotherapy available in the U.S. for these indications. Health Canada approved LOQTORZI in October 2025, and the company granted Apotex an exclusive license to commercialize the product in Canada.
Coherus' pipeline includes two mid-stage clinical candidates: casdozokitug, an investigational IL-27 antagonist antibody targeting hepatocellular carcinoma and other cancers, which received orphan drug designation from the FDA; and tagmokitug, an investigational afucosylated IgG1 antibody targeting CCR8 on regulatory T cells, currently in clinical trials for head and neck squamous cell carcinoma and other solid tumors.
The company developed LOQTORZI in collaboration with Junshi Biosciences Co., Ltd. and maintains global rights to develop and commercialize casdozokitug and tagmokitug. Coherus commercializes LOQTORZI in the United States and Puerto Rico through wholesale specialty distribution channels. The company is executing a coordinated initiative to onshore biomanufacturing processes for its product and pipeline candidates to the United States. Coherus possesses scientific expertise, manufacturing capabilities, and U.S.-based experience across oncology clinical development, regulatory affairs, sales, and medical affairs. More information is available at www.coherusoncology.com.
Company details
- Sector
- Healthcare
- Industry
- Biological Products
- Headquarters
- REDWOOD CITY, CA
- Fiscal year end
- December
- CIK
- 1512762
- SIC
- 2836
Financial performance, year by year
Fiscal 2014–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Coherus Oncology, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Coherus Oncology, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Coherus Oncology, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Coherus Oncology, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Coherus Oncology, Inc.'s last four quarterly filings that the numbers alone won't show?”